Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In add...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Giampieri, Riccardo, Prete, Michela del, Prochilo, Tiziana, Puzzoni, Marco, Pusceddu, Valeria, Pani, Fabiana, Maccaroni, Elena, Mascia, Roberta, Baleani, Maria Giuditta, Meletani, Tania, Berardi, Rossana, Lanzillo, Anna Maria, Mariotti, Stefano, Zaniboni, Alberto, Cascinu, Stefano, Scartozzi, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380985/
https://ncbi.nlm.nih.gov/pubmed/28378839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep45703
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados